预防中风的不同类型抗高血压药物的比较疗效:随机对照试验的网络元分析
Ding Yu1, Jun-Xia Li2, Yuan Cheng3
1Heart Center, The First Hospital of Hebei Medical University, Shijiazhuang, China.
PloS one
|February 21, 2025
概括
ангиотензин转化酶抑制剂 (ACEI),通道阻断剂 (CCB) 和利尿剂 (DI) 在高血压患者中有效预防中风和死亡率. 组合疗法,如ACEI加上CCBs,可以增强对中风的保护.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 高血压是中风和心血管死亡的主要危险因素.
- 确定有效的抗高血压药物策略对于患者的治疗结果至关重要.
研究的目的:
- 为了比较各种抗高血压药物在预防高血压患者中风的疗效.
- 评估药物类别和子类别对中风,全因死亡率和心血管死亡率的影响.
主要方法:
- 在主要数据库 (PubMed,Embase,Cochrane Library,ClinicalTrials.gov) 进行了系统的文献搜索.
- 进行了88项随机对照试验 (RCT) 的贝叶斯网络元分析,涉及487,076名患者.
- 该分析评估了药物对中风,所有原因死亡率和心血管死亡率的影响.
主要成果:
- 在总人口中,与安慰剂相比,ACEI,ARB,CCB和DI降低了中风和死亡率.
- 在减轻中风方面,CCB和DI优于β-阻断剂,ACEI和ARB.
- 对于高血压患者来说,ACEI,CCB和DI表现出优于安慰剂;ARB对心血管死亡率的有效性较低.
- 迪皮里丁CCB和类似 thiazide 的利尿剂是有效的,但并非所有利尿剂子类.
- 组合疗法 (ACEI+CCBs) 对中风和死亡率显示出比单一疗法更大的益处.
结论:
- 建议在高血压患者中预防中风和死亡率,使用ACEI,二皮里丁CCB和类似 thiazide 的利尿剂.
- 组合疗法,特别是ACEI和CCB,可以提供对中风的优越保护.
- 这些发现支持基于药物疗效的个性化抗高血压治疗策略.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
01:22Dose-Response Relationship: Potency and Efficacy
4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
702
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
702
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
761
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
761